Amgen Wraps Up Phase III Trial For Soliris Biosimilar

Amgen Able To Launch Eculizumab Biosimilar In 2025 Under Settlement Agreement

 
• By Rosalind Rei

Amgen’s proposed ABP 959 eculizumab biosimilar matches Alexion’s Soliris at controlling intravascular haemolysis in paroxysmal nocturnal haemoglobinuria patients. 

Clinical trial
Amgen has several biosimilars in Phase III development • Source: Shutterstock

More from Biosimilars

More from Products